Ana C deCarvalho
Overview
Explore the profile of Ana C deCarvalho including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
2242
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Berezovsky A, Nuga O, Datta I, Bergman K, Sabedot T, Gurdziel K, et al.
PLoS One
. 2025 Feb;
20(2):e0315171.
PMID: 39919036
Glioblastoma (GBM) tumors exhibit extensive genomic, epigenomic, and transcriptional diversity, with significant intratumoral heterogeneity, complicating standard treatment approaches involving radiation (RT) and the DNA-alkylating agent temozolomide (TMZ). In this study,...
2.
Kim B, Mondal S, Kenyon E, Chen M, Mallett C, deCarvalho A, et al.
J Vis Exp
. 2024 Oct;
(211).
PMID: 39400152
Glioblastoma multiforme (GBM) is the most common and aggressive form of primary brain malignancy for which there is no cure. The blood-brain barrier is a significant hurdle in the delivery...
3.
Berezovsky A, Nuga O, Datta I, Bergman K, Sabedot T, Gurdziel K, et al.
bioRxiv
. 2024 Oct;
PMID: 39386580
Glioblastoma (GBM) tumors represents diverse genomic epigenomic, and transcriptional landscapes, with significant intratumoral heterogeneity that challenges standard of care treatments involving radiation (RT) and the DNA-alkylating agent temozolomide (TMZ). In...
4.
Malta T, Sabedot T, Morosini N, Datta I, Garofano L, Vallentgoed W, et al.
Cancer Res
. 2023 Dec;
84(5):741-756.
PMID: 38117484
Significance: Standard treatments are related to loss of DNA methylation in IDHmut glioma, resulting in epigenetic activation of genes associated with tumor progression and alterations in the microenvironment that resemble...
5.
Herrgott G, Snyder J, She R, Malta T, Sabedot T, Lee I, et al.
Nat Commun
. 2023 Sep;
14(1):5669.
PMID: 37704607
Recurrence of meningiomas is unpredictable by current invasive methods based on surgically removed specimens. Identification of patients likely to recur using noninvasive approaches could inform treatment strategy, whether intervention or...
6.
Lubanska D, Alrashed S, Mason G, Nadeem F, Awada A, DiPasquale M, et al.
Sci Rep
. 2022 Jul;
12(1):12078.
PMID: 35840697
Glioblastoma is one of the most aggressive types of cancer with success of therapy being hampered by the existence of treatment resistant populations of stem-like Tumour Initiating Cells (TICs) and...
7.
Herrgott G, Asmaro K, Wells M, Sabedot T, Malta T, Mosella M, et al.
Neuro Oncol
. 2022 Feb;
24(7):1126-1139.
PMID: 35212383
Background: DNA methylation abnormalities are pervasive in pituitary neuroendocrine tumors (PitNETs). The feasibility to detect methylome alterations in circulating cell-free DNA (cfDNA) has been reported for several central nervous system...
8.
Barekatain Y, Ackroyd J, Yan V, Khadka S, Wang L, Chen K, et al.
Nat Commun
. 2021 Jul;
12(1):4228.
PMID: 34244484
Homozygous deletion of methylthioadenosine phosphorylase (MTAP) in cancers such as glioblastoma represents a potentially targetable vulnerability. Homozygous MTAP-deleted cell lines in culture show elevation of MTAP's substrate metabolite, methylthioadenosine (MTA)....
9.
Zhu Y, Gujar A, Wong C, Tjong H, Ngan C, Gong L, et al.
Cancer Cell
. 2021 Apr;
39(5):694-707.e7.
PMID: 33836152
Extrachromosomal, circular DNA (ecDNA) is emerging as a prevalent yet less characterized oncogenic alteration in cancer genomes. We leverage ChIA-PET and ChIA-Drop chromatin interaction assays to characterize genome-wide ecDNA-mediated chromatin...
10.
Mosella M, Sabedot T, C Silva T, Malta T, Segato Dezem F, Asmaro K, et al.
Neuro Oncol
. 2021 Feb;
23(8):1292-1303.
PMID: 33631002
Background: Distinct genome-wide methylation patterns cluster pituitary neuroendocrine tumors (PitNETs) into molecular groups associated with specific clinicopathological features. Here we aim to identify, characterize, and validate methylation signatures that objectively...